![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage
|
|
|
Reported by Jules Levin
CROI 2014 Boston, MA March 3-6
Teresa Ng1, Thomas Reisch1, Tim Middleton1, Keith McDaniel1, Dale Kempf1, Liangjun Lu1, Guoqiang Wang2, Lijuan Jiang2, Yat Sun Or2, Tami Pilot-Matias1
1AbbVie Inc., North Chicago, Illinois, United States; 2Enanta Pharmaceuticals Inc., Watertown, Massachusetts, United States
![HCV1.gif](../images/030514/030513-3/HCV1.gif)
![HCV2.gif](../images/030514/030513-3/HCV2.gif)
![HCV3.gif](../images/030514/030513-3/HCV3.gif)
![HCV4.gif](../images/030514/030513-3/HCV4.gif)
![HCV5.gif](../images/030514/030513-3/HCV5.gif)
![HCV6.gif](../images/030514/030513-3/HCV6.gif)
![HCV7.gif](../images/030514/030513-3/HCV7.gif)
![HCV8.gif](../images/030514/030513-3/HCV8.gif)
![HCV9.gif](../images/030514/030513-3/HCV9.gif)
![HCV10.gif](../images/030514/030513-3/HCV10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|